Integra LifeSciences Holdings (IART) 2019年年度报告「NASDAQ」.pdf

1、2019 Annual ReportTo Our ShareholdersJust a few days before her high school graduation in 1996,Katy Stowe suffered third-degree burns from a car accident that nearly claimed her life.Integra was there to help Katy recover from her injuries.Eighteen-month-old Anthony“Tony”LaRosa was rushed to the eme

2、rgency room with a traumatic brain injury after being struck by an SUV one fateful day in 2001.Integra was there to help Tony beat the odds of his grim prognosis.In 2016,Brook Zemel developed an abdominal hernia following surgery to remove a tumor from his pancreas.The hernia not only caused physica

3、l disfigurement,but also affected his emotional well-being.Integra was there to help him heal and recover.We closed 2019 looking back at the millions of patients who have benefited from our Integra instruments,neurocritical care and electrosurgical devices,regenerative technologies and extremity ort

4、hopedics.For 30 years,we have been privileged to make products that have such a positive impact on the lives of people around the world.Integra has been and always will be there to help surgeons limit uncertainty,so patients can get back to doing what matters most spending time with their families a

5、nd living normal and productive lives.Brook ZemelIntegra PatientPositioning for Accelerated Growth2019 was a year of significant integration work and operational investments that will position Integra LifeSciences for accelerated organic growth in the years ahead.Integra revenues grew organically by

6、 4.8 percent to$1.5 billion and adjusted earnings per share grew double digits for the sixth consecutive year.Our operating cash flow was$231 million,exceeding the top end of our guidance range for the year.As part of our ongoing strategy to optimize our capital structure,we acted on favorable marke